Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Tyverb opvejer risiciene i kombination med capecitabin til behandling af patienter med fremskreden eller metastatisk brystkræft, hvis tumorer har en overproduktion af ErbB2 (HER2).
The Committee for Medicinal Products for Human Use (CHMP) decided that Tyverb’ s benefits are greater than its risks, in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress ErbB2 (HER2).